Article

Daily Medication Pearl: Atorvastatin Calcium (Lipitor)

Lipitor is an inhibitor of HMG-CoA reductase indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels.

Indication: Lipitor is an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels and reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina in patients without coronary heart disease, but with multiple risk factors.

Insight:

  • Dosing: Dose range 10 to 80 mg once daily.
  • Dosage forms: 10, 20, 40, and 80 mg tablets
  • Adverse events: The most reported adverse events (incidence ≥ 2%) in patients treated with Lipitor in placebo-controlled trials regardless of causality were nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection.
  • Mechanism of action: Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3­ methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.
  • Manufacturer: Pfizer

Source: label (fda.gov)

Related Videos
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC